Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

3.2%

1 terminated out of 31 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

19%

6 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results92% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (1)
P 1 (5)
P 2 (4)
P 3 (3)
P 4 (3)

Trial Status

Completed12
Recruiting11
Unknown3
Not Yet Recruiting1
Terminated1
Active Not Recruiting1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT07534267Not Yet Recruiting

Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea

NCT05512949Phase 2CompletedPrimary

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

NCT05740982Phase 2CompletedPrimary

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

NCT05988203Phase 1CompletedPrimary

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

NCT05879965RecruitingPrimary

Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk

NCT06579885CompletedPrimary

Ocular Complications of Mpox in the Democratic Republic Congo

NCT05534165Phase 3SuspendedPrimary

Tecovirimat in Non-hospitalized Patients With Monkeypox

NCT05734508Phase 4CompletedPrimary

Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC

NCT07377175Phase 1Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.

NCT05654883Enrolling By InvitationPrimary

New York City Observational Study of Mpox Immunity

NCT05559099Phase 2CompletedPrimary

Tecovirimat for Treatment of Monkeypox Virus

NCT06771479Phase 1RecruitingPrimary

A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

NCT06223919Phase 3Active Not RecruitingPrimary

Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia

NCT05965427CompletedPrimary

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

NCT05745987Phase 4RecruitingPrimary

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

NCT06885853RecruitingPrimary

Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

NCT05597735Phase 3RecruitingPrimary

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

NCT06156566Phase 4RecruitingPrimary

European Trial Into Mpox Infection

NCT06045923RecruitingPrimary

Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV

NCT05562323RecruitingPrimary

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study

Scroll to load more

Research Network

Activity Timeline